Compare Amphastar Pharmaceuticals Inc (AMPH) vs Canadian Natural Resources Ltd. (CNQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Canadian Natural Resources Ltd. — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Canadian Natural Resources Ltd. trades at $47.82 (market cap $97.27B). The key difference: Canadian Natural Resources Ltd. is far larger — about 112.6× Amphastar Pharmaceuticals Inc's market cap, and Canadian Natural Resources Ltd. pays a 3.76% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | CNQ | |
|---|---|---|
Market Cap | $863.95M | $97.27B |
Sector | Health | Energy |
52-Week High | $30.81 | $50.55 |
52-Week Low | $16.87 | $29.31 |
Enterprise Value | $1.26B | $107.68B |
Dividend Yield | — | 3.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Canadian Natural Resources (CNQ) trades at $45.51, up 0.13% with strong technical momentum and bullish moving average signals. The company delivered impressive Q2 2026 results with EPS of $1.53 beating estimates by 7%, driven by record production and operational efficiency. Financials show robust profitability with 22.87% net margin and 26.69% ROE, while valuation remains attractive at 11.35 P/E. Recent news highlights dividend consistency and institutional accumulation.
CNQ presents a compelling investment case with strong fundamentals, consistent earnings beats, and shareholder returns through dividends. Key opportunities include production growth guidance increases and favorable oil pricing exposure. Risks include commodity price volatility and rising capital expenditures. Analyst consensus remains strongly bullish with 75% buy ratings supporting upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Canadian Natural Resources Ltd.
Canadian Natural Resources is one of the largest oil and natural gas producers in western Canada, supplemented by operations in the North Sea and Offshore Africa. The company's portfolio includes light and medium oil, heavy oil, bitumen, synthetic oil, natural gas liquids, and natural gas. Production averaged 1.16 million barrels of oil equivalent per day in 2020, and the company estimates that it holds over 11.5 billion boe of proven and probable crude oil and natural gas reserves.
Read more on CNQ →
